Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Association between artificial intelligence (AI) -assisted tumor AREG and EREG immunohistochemistry (IHC) and outcomes from anti-EGFR therapy during the routine management of metastatic colorectal cancer (mCRC): An observational cohort study.
Authors
Christopher Williams
Leeds Cancer Centre, Leeds, United Kingdom;
Christopher Williams , Faye Elliott , Mike Shires , Henry Wood , Liping Zhang , Zuo Zhao , Isaac Bai , Dongyao Yan , Faranak Aghaei , Uday Kurkure , Chris Bacon , Sarah E Coupland , Simon Cross , D Chas Mangham , Abhik Mukherjee , Jenny F. Seligmann , Nicholas West , Shalini Singh , Kandavel Shanmugam , Philip Quirke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 203)
DOI
10.1200/JCO.2023.41.4_suppl.203
Abstract #
203
Poster Bd #
L5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442).
First Author: Christopher Williams
Poster
2017 ASCO Annual Meeting
Cost-effectiveness of front-line trials in metastatic colorectal cancer: Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs..
First Author: Andrea Bonetti
Poster
2017 Gastrointestinal Cancers Symposium
A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study.
First Author: Eiji Shinozaki
Poster
2016 Gastrointestinal Cancers Symposium
Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.
First Author: Stefano Cascinu